Patient P-01327

Synthetic patientNBL-101 · Day 120 · 55–64 · M · baseline S01Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

57%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S01
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 SC-12 recommended — Supportive Compound SC-12
Day 54 Patient accepted — Started SC-12 in the companion
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 60 GI symptom burden −18% vs expected — Supportive Compound SC-12
Day 64 GI symptom burden −25% vs expected — GI Support Protocol GI-04
Day 66 Tolerance state changed — Unstable → Improving
Day 70 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Inflammatory activity+6
Toxicity-5
GI instability+4

What helped?

Supportive Compound SC-12Day 53
Result: symptom burden −18%
GI Support Protocol GI-04Day 55
Result: symptom burden −25%

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 50
- WearableHRV 29 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 29/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 52 and rising
Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
Autonomic recovery ↓20
- Wearable3,121 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.2 · butyrate capacity 29/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 34 ms
Sleep: 6.9 h
Steps: 2,077
Resting HR: 69 bpm

Daily log: GI score 52, nutritional resilience 45, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01339	52%	S14	GI-04	improved	54
P-01406	51%	S18	GI-04	improved	50
P-01573	51%	S14	GI-04	improved	49
P-01614	51%	S14	GI-04	improved	53
P-01365	49%	S14	SC-12	improved	49
P-01473	49%	S14	GI-04	improved	51
P-01661	49%	S03	GI-04	improved	52
P-01775	49%	S14	SC-12	improved	48
P-01496	48%	S14	SC-12	improved	46
P-01501	48%	S14	GI-04	improved	45
P-01595	48%	S14	GI-04	no change	51
P-01706	48%	S14	GI-04	improved	55